| P50 | author | David Cella | Q62568473 |
| P2093 | author name string | David Victorson | |
| | Mehul Soni | |
| P2860 | cites work | The file drawer problem and tolerance for null results | Q24273204 |
| | Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group | Q30584392 |
| | Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma | Q30749793 |
| | Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study | Q33329809 |
| | Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group | Q33330616 |
| | Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer | Q33905833 |
| | Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial | Q34271566 |
| | Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer | Q36080357 |
| | Do patients with advanced breast cancer benefit from chemotherapy? | Q36115775 |
| | A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma | Q38149065 |
| | Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. | Q39419888 |
| | Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study | Q39431338 |
| | Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer | Q39436075 |
| | Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma | Q39447961 |
| | Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor | Q39472047 |
| | Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? | Q40789907 |
| | Misleading meta-analysis. "Fail safe N" is a useful mathematical measure of the stability of results | Q43186191 |
| | What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. | Q53450591 |
| | Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. | Q53513654 |
| | Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. | Q53525794 |
| | Primary, Secondary, and Meta-Analysis of Research | Q56094336 |
| | Prospective Exploratory Analysis of the Association Between Tumor Response, Quality of Life, and Expenditures Among Patients Receiving Paclitaxel Monotherapy for Refractory Metastatic Breast Cancer | Q57578589 |
| | Phase II study of vinorelbine in patients with malignant pleural mesothelioma | Q73250833 |
| | A statistical simulation study finds discordance between WHO criteria and RECIST guideline | Q80068702 |
| | Tumor response and survival end points in clinical trials: a clinician's perspective | Q81135735 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| P304 | page(s) | 494-504 | |
| P577 | publication date | 2006-02-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Metaanalysis of the correlation between radiographic tumor response and patient-reported outcomes | |
| P478 | volume | 106 | |